AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06441955 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary approach
Description: The aim of utilizes psychology-applied science and science in nursing frameworks to address health disparities and promote health and wellness across the health span to improve patient population outcomes, evaluate cost-effectiveness, and patient health literacy competencies. The experimental framework of a compilation of the bio-psychosocial model, Eric Erickson developmental stages, AI/AML, and cognitive learning theories address system decision making factors, for sound decision making and behavioral change cognitive behavioral therapies protocol segmentation demographic and urban areas affected by social-economic access to healthcare and related ethical stance of United States healthcare policy developmental outlines. Biology plays a role in the content of development stages, and the great debate of nurture vs. nature sets the foundation for addressing the psychosocial approach to healthcare integration as an applied science model for strengthening primary services and improving
Study NCT06458595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH658
Description: KH658 Ophthalmic Injection
Study NCT05617794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion Optics Technology (DOT) Pattern Spectacle Lens
Description: DOT Pattern Spectacle Lens
Study NCT05617794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Spectacle Lens
Description: Control Spectacles
Study NCT05652283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
Study NCT05652283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
Study NCT05946746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PeptiStrong
Description: PeptiStrong is a protein hydrolysate derived from Vicia faba. It is a free-flowing powder, pale yellow in colour. For the purposes of the trial, PeptiStrong will be encapsulated in size '00' hydroxypropyl methylcellulose capsules.
Study NCT05946746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SMCC silicated micro-crystalline cellulose
Description: Placebo - SMCC silicated microcrystalline cellulose (INCI name: MCC, cellulose gel), For the purposes of the trial, SMCC will be encapsulated in size '00' hydropropyl methylcellulose.
Study NCT04975165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
Study NCT05242367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modius Spero active device
Description: Battery powered non-invasive neurostimulation device
Study NCT05242367 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Placebo comparator sham device (no active stimulation)
Study NCT05975996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide added to standard immunosuppressive therapy with herombopag
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
Study NCT06393608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epsom salt
Description: Epsom salt solution in water, 25% concentration
Study NCT06393608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study NCT06161506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elidah Device
Description: The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
Study NCT06528132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) (enhanced with peer supporters)
Description: Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.
Study NCT06528132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: social worker-led MBI (without peer supporters)
Description: Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
Study NCT05832307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Existing Influenza Vaccination Practices
Description: Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
Study NCT05832307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized inpatient influenza vaccination program
Description: Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
Study NCT05853575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: KRAS G12C inhibitor
Study NCT04690582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
Study NCT04690582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
Study NCT04690582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Plan (CRP)
Description: The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
Study NCT04690582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention (SPI)
Description: The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
Study NCT04690582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Assessment
Description: The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan.
Study NCT04352231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fiber Diet Intervention
Description: Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
Study NCT04352231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Fiber Diet Intervention
Description: Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
Study NCT05880784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reinforcement of Peer coaching and clinical audit
Description: The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
Study NCT05880784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuation of usual practice without intervention
Description: No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
Study NCT04383639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)
Description: The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
Study NCT04383639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)
Description: The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
Study NCT05053230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IM@Home
Description: Participants in the IM@Home group will receive a 12-week virtual, synchronous, mind-body and fitness program. The Classes will be conducted via Zoom video conferencing platform. Patients will choose from a variety of weekly classes, occurring one to four times per week. An Integrative Medicine Service (IMS) clinical therapist (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting will lead each session. Activities range from more movement-based (fitness, yoga, dance therapy, or tai chi) to meditative-based classes (meditation, guided meditation, or music therapy). All clinicians will provide an overview of the session, 25 to 40 minutes of content, and five minutes for feedback and discussion. Each class lasts 30 to 45 minutes with optional audio or video participant participation and group chat.
Study NCT05053230 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced usual care
Description: Patients in the enhanced usual care will receive usual care. In addition, once enrolling into the trial, they will be given a handout to encourage them to visit the MSK's multimedia page on the Integrative Medicine website to access pre-recorded, on-demand meditation audio or video recordings for meditation, guided imagery, and relaxation.
Study NCT06274801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seralutinib
Description: Capsule containing seralutinib
Study NCT06274801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gereic Dry Powder Inhaler
Description: Generic dry powder inhaler for seralutinib delivery
Study NCT05732623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Description: The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~* date of birth~* sex~* ethnicity~* weight (kg)~* height (m)~* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~* country where they live permanently~* tobacco smoking at the time of eoCRC diagnosis and at 18 years old~* sitting time~* TV-viewing time~* moderate-to-vigorous physical activity (MVPA)~* waist circumference (cm)~* home blood pressure levels (mmHg)~* fasting blood glucose (mg/dl)~* regular consumption of aspirin/NSAID and years of consumptions~* calcium and folate supplements and years of consumptions~* oral contraceptive agents and years of consumptions~* post-menopausal hormones and years of consumptions
Study NCT06547216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1020
Description: AOC 1020 will be administered via intravenous (IV) infusion
Study NCT05899764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~* Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12.
Study NCT05550337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene 0.005 % Topical Cream
Description: Cream
Study NCT05550337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKLIEF®
Description: Cream
Study NCT05550337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream
Study NCT06640582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV
Study NCT05694507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Well-being Chatbot
Description: The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
Study NCT04774185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New hearing aid loudspeaker
Description: The new hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
Study NCT04774185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hearing aid loudspeaker
Description: The standard hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
Study NCT05347537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization
Description: Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
Study NCT05347537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clamshell exercise
Description: As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
Study NCT06640582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study NCT06640582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study NCT06640582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study NCT06640582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT06642961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: GR1802 will be administered SC.
Study NCT06642961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered SC.
Study NCT06639737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative stroke volume optimization
Description: Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia. Fluids bolus of 250 ml of cristalloids will be successively administered until the sub aortic velocity time integral increase will be \< 10%
Study NCT06639737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post induction stroke volume optimization
Description: Optimization of stroke volume following induction of general anesthesia using oesophageal stroke volume measurement. 250 ml bolus of cristalloids succesively administered until the stroke volume increase \<10%
Study NCT04702607 — intervention group
Intervention type: PROCEDURE
Intervention: contrast enhanced 4DCT
Description: Functional Lung Imaging with DECT and 4DCT
Study NCT06168968 — intervention group
Intervention type: BEHAVIORAL
Intervention: Life and Medication Recommendations
Description: Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
Study NCT06639373 — intervention group
Intervention type: OTHER
Intervention: Specialized clinical service access
Description: A new model of addiction care that will offer comprehensive and coordinated service delivery
Study NCT06334211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-020
Description: MMP-12 inhibitor
Study NCT06334211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06639555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP( platelet rich plasma)
Description: regenerative therapy with PRP for vertical bone defects
Study NCT06639555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMD (Enamel Matrix Derivative)
Description: regenerative therapy with EMD for vertical bone defects
Study NCT06639555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration (barrier membrane)
Description: guided tissue regeneration with barrier membrane alone for vertical bone defects
Study NCT06639555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration(barrier membrane and PRP)
Description: guided tissue regeneration with barrier membrane and PRP for vertical bone defects
Study NCT06636851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker and defibrillator
Description: Permenant pacemaker implantation with lead fixed to the RV Septal location
Study NCT06636851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker and defibrillator
Description: Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
Study NCT06643208 — intervention group
Intervention type: DRUG
Intervention: TACE-HAIC, Envafolimab and Lenvatinib
Description: TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
Study NCT06643546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theoretical training
Description: received only theoretical breastfeeding training